{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:19:52Z","timestamp":1788200392246,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13555-020-00481-w","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T23:08:32Z","timestamp":1609974512000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-8425","authenticated-orcid":false,"given":"Jane J.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Faletsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"4","key":"481_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1610-0387.2007.06274.x","volume":"5","author":"K Degitz","year":"2007","unstructured":"Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5(4):316\u201323.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2 Suppl","key":"481_CR2","first-page":"4","volume":"76","author":"GF Webster","year":"2005","unstructured":"Webster GF. The pathophysiology of acne. Cutis. 2005;76(2 Suppl):4\u20137.","journal-title":"Cutis"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.15659.1","volume":"7","author":"E Platsidaki","year":"2018","unstructured":"Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7:F1000 Faculty Rev-1953.","journal-title":"F1000Res"},{"issue":"2 Pt 3","key":"481_CR4","first-page":"S34","volume":"39","author":"GM White","year":"1999","unstructured":"White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1999;39(2 Pt 3):S34\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"481_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamadermatol.2020.0464","volume":"156","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS. A new class of topical acne treatment addressing the hormonal pathogenesis of acne. JAMA Dermatol. 2020;156(6):619\u201320.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"481_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","volume":"165","author":"V Trifu","year":"2011","unstructured":"Trifu V, Tiplica G, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177\u201383.","journal-title":"Br J Dermatol"},{"issue":"6","key":"481_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert A, Thiboutot D, Stein Gold L, et\u00a0al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621\u201330.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"481_CR8","first-page":"563","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"481_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1060028019873111","volume":"54","author":"W Haidari","year":"2019","unstructured":"Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline review. Ann Pharmacother. 2019;54(2):164\u201370.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"481_CR10","doi-asserted-by":"publisher","first-page":"e01297","DOI":"10.1128\/AAC.01297-18","volume":"63","author":"G Zhanel","year":"2019","unstructured":"Zhanel G, Critchley I, Lin L, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2019;63(1):e01297.","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"481_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/fmb-2019-0199","volume":"14","author":"AY Moore","year":"2019","unstructured":"Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235\u201342.","journal-title":"Future Microbiol"},{"issue":"11","key":"481_CR12","first-page":"E53","volume":"12","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Green LJ, Lain EL, et\u00a0al. Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study. J Clin Aesthet Dermatol. 2019;12(11):E53.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"481_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-019-00423-z","volume":"20","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345\u201365.","journal-title":"Am J Clin Dermatol"},{"key":"481_CR14","first-page":"1","volume":"29","author":"HPM Gollnick","year":"2015","unstructured":"Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29:1\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"481_CR15","first-page":"s51","volume":"17","author":"A Chien","year":"2018","unstructured":"Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12):s51.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"481_CR16","first-page":"638","volume":"12","author":"HE Baldwin","year":"2013","unstructured":"Baldwin HE, Nighland M, Kendall C, Mays DA, Grossman R, Newburger J. 40 years of topical tretinoin use in review. J Drugs Dermatol. 2013;12(6):638.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"481_CR17","first-page":"146","volume":"83","author":"G Webster","year":"2009","unstructured":"Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis. 2009;83(3):146.","journal-title":"Cutis"},{"issue":"2","key":"481_CR18","first-page":"442","volume":"179","author":"J Aubert","year":"2018","unstructured":"Aubert J, Piwnica D, Bertino B, et\u00a0al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene. Br J Dermatol. 2018;179(2):442\u201356.","journal-title":"Br J Dermatol"},{"issue":"6","key":"481_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","volume":"80","author":"J Tan","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, et\u00a0al. Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"481_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jdv.15794","volume":"34","author":"U Blume-Peytavi","year":"2020","unstructured":"Blume-Peytavi U, Fowler J, Kem\u00e9ny L, et\u00a0al. Long-term safety and efficacy of trifarotene 50 \u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"481_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.36849\/JDD.2020.3977","volume":"19","author":"EA Tanghetti","year":"2020","unstructured":"Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"481_CR22","first-page":"1084","volume":"17","author":"SK Tyring","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"481_CR23","first-page":"542","volume":"18","author":"EA Tanghetti","year":"2019","unstructured":"Tanghetti EA, Kircik LH, Green LJ, et\u00a0al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.","journal-title":"J Drugs Dermatol."},{"issue":"2","key":"481_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/09546634.2019.1587884","volume":"31","author":"JC Harper","year":"2020","unstructured":"Harper JC, Roberts WE, Zeichner JA, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups. J Dermatol Treat. 2020;31(2):160\u20137.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"481_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/1523-1747.ep12472325","volume":"100","author":"H Akamatsu","year":"1993","unstructured":"Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5\u03b1-dihydrotestosterone in vitro. J Investig Dermatol. 1993;100(5):660\u20132.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"481_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et\u00a0al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"481_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaad.2017.04.016","volume":"77","author":"JS Barbieri","year":"2017","unstructured":"Barbieri JS, James WD, Margolis DJ. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: a retrospective analysis, 2004\u20132013. J Am Acad Dermatol. 2017;77(3):456-463.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"481_CR28","first-page":"30","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Rosen T, Palceski D, Rueda MJ. Patient awareness of antimicrobial resistance and antibiotic use in acne vulgaris. J Clin Aesthet Dermatol. 2019;12(6):30\u201341.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"481_CR29","first-page":"632","volume":"17","author":"JS Barbieri","year":"2018","unstructured":"Barbieri JS, Choi JK, Mitra N, Margolis DJ. Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010\u20132016. J Drugs Dermatol. 2018;17(6):632.","journal-title":"J Drugs Dermatol"},{"key":"481_CR30","unstructured":"Guzman AK, Barbieri JS. Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris. J Am Acad Dermatol. 2020;S0190-9622(20)31141\u20135."},{"issue":"4","key":"481_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","volume":"83","author":"C Wei","year":"2020","unstructured":"Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI, Friedman AJ. Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis. J Am Acad Dermatol. 2020;83(4):1021\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"7868","key":"481_CR32","first-page":"17","volume":"345","author":"IS Mackenzie","year":"2012","unstructured":"Mackenzie IS, MacDonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012;345(7868):17.","journal-title":"BMJ"},{"issue":"9","key":"481_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","volume":"151","author":"M Plovanich","year":"2015","unstructured":"Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941\u20134.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"481_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijwd.2019.04.024","volume":"5","author":"RM Thiede","year":"2019","unstructured":"Thiede RM, Rastogi S, Nardone B, et\u00a0al. Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (research on adverse drug events and reports) program. Int J Women\u2019s Dermatol. 2019;5(3):155\u20137.","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"2","key":"481_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","volume":"18","author":"AM Layton","year":"2017","unstructured":"Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169\u201391.","journal-title":"Am J Clin Dermatol"},{"key":"481_CR36","unstructured":"Randomized double-blind study on the benefit of spironolactone for treating acne of adult woman. (FASCE). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03334682. Accessed 12 Oct 2020."},{"key":"481_CR37","unstructured":"Spironolactone for adult female acne: a pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women. https:\/\/www.southampton.ac.uk\/ctu\/trialportfolio\/listoftrials\/safa.page. Accessed 28 Sept 2020."},{"issue":"2","key":"481_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","volume":"80","author":"JS Barbieri","year":"2019","unstructured":"Barbieri JS, Spaccarelli N, Margolis DJ, James WD. Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"481_CR39","unstructured":"Medication guide: accutane. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/018662s061MedGuide.pdf. Accessed 28 Sept 2020."},{"issue":"1","key":"481_CR40","first-page":"1","volume":"152","author":"YH Lee","year":"2015","unstructured":"Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elera G, Kirby JS. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol. 2015;152(1):1\u201310.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"481_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","volume":"82","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J. The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol. 2020;82(1):72\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"481_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000505451","volume":"236","author":"E Tkachenko","year":"2020","unstructured":"Tkachenko E, Sharma P, Mostaghimi A. Abnormal baseline lab results rarely lead to treatment modification for patients on isotretinoin. Dermatology. 2020;236(6):517\u201320.","journal-title":"Dermatology."},{"issue":"1","key":"481_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2020.04.106","volume":"84","author":"P Sharma","year":"2020","unstructured":"Sharma P, Tkachenko E, Mostaghimi A. A retrospective evaluation of routine isotretinoin laboratory monitoring in patients above 35 years old. J Am Acad Dermatol. 2020;84(1):201\u20132.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"481_CR44","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/bjd.15207","volume":"177","author":"D Opel","year":"2017","unstructured":"Opel D, Kramer ON, Chevalier M, Bigby M, Albrecht J. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol. 2017;177(4):960\u20136.","journal-title":"Br J Dermatol"},{"issue":"10","key":"481_CR45","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","volume":"155","author":"E Tkachenko","year":"2019","unstructured":"Tkachenko E, Singer S, Sharma P, Barbieri J, Mostaghimi A. US food and drug administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin. JAMA Dermatol. 2019;155(10):1175.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"481_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2020.02.022","volume":"83","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS, Roe AH, Mostaghimi A. Simplifying contraception requirements for iPLEDGE: a decision analysis. J Am Acad Dermatol. 2020;83(1):104\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"481_CR47","doi-asserted-by":"publisher","first-page":"e0210445","DOI":"10.1371\/journal.pone.0210445","volume":"14","author":"A Charrow","year":"2019","unstructured":"Charrow A, Xia FD, Lu J, Waul M, Joyce C, Mostaghimi A. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era. PLoS ONE. 2019;14(3):e0210445.","journal-title":"PLoS ONE"},{"issue":"3","key":"481_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamadermatol.2019.4818","volume":"156","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J. Association of race\/ethnicity and sex with differences in health care use and treatment for acne. JAMA Dermatol. 2020;156(3):312\u20139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"481_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamadermatol.2019.3270","volume":"156","author":"JS Barbieri","year":"2019","unstructured":"Barbieri JS, Frieden IJ, Nagler AR. Isotretinoin, patient safety, and patient-centered care\u2014time to reform iPLEDGE. JAMA Dermatol. 2019;156(1):21\u20132.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"481_CR50","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamadermatol.2019.1416","volume":"155","author":"S Singer","year":"2019","unstructured":"Singer S, Tkachenko E, Sharma P, Barbieri JS, Mostaghimi A. Psychiatric adverse events in patients taking isotretinoin as reported in a food and drug administration database from 1997 to 2017. JAMA Dermatol. 2019;155(10):1162\u20136.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"481_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1203475419838553","volume":"23","author":"E Tkachenko","year":"2019","unstructured":"Tkachenko E, Singer SB, Sharma P, Barbieri J, Mostaghimi A. FDA reports of alopecia as an adverse event to isotretinoin. J Cutan Med Surg. 2019;23(4):451\u20132.","journal-title":"J Cutan Med Surg"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00481-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T21:22:10Z","timestamp":1674854530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00481-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00481-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}